ArticleToxicology reports2019

Preclinical evaluation of Amblyomin-X, a Kunitz-type protease inhibitor with antitumor activity.

Durvanei A Maria et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.